---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-037654"
form_type: "8-K"
ticker: null
cik: "0000811240"
company_name: "BIOLASE, INC"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:42:03.797171+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BIOLASE closes $7M public offering; Nasdaq extends compliance deadline to March 31, 2024

## Summary
- Raised ~$7.0M gross in public offering of 16M units at $0.44/unit with Class A and Class B warrants.
- Class A warrants exercisable at $0.66/share for 5 years; Class B warrants at $0.748 upon stockholder approval.
- Issued investor warrant for 2,221,880 shares; December 2023 warrants repriced to $0.2256 per share.
- Nasdaq granted extension to meet minimum equity rule until March 31, 2024, conditioned on offering closing.
- Post-offering shares outstanding: 19,195,024 (including 7.2M from pre-funded warrant exercises).

## SEC filing metadata
- accession: 0001193125-24-037654
- form_type: 8-K
- cik: 0000811240
- company_name: BIOLASE, INC
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811240/000119312524037654/0001193125-24-037654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811240/000119312524037654/d780376d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-037654
- JSON: https://secwatch.observer/filing/0001193125-24-037654.json
- Plain text: https://secwatch.observer/filing/0001193125-24-037654.txt

## Key facts
- Listing & Compliance Notices
  BIOLASE, INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)
  source text: February 13, 2024, the Company received notice from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff had determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the “Rule”). The Rule requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. As previously announced, on November 14, 2023, the Company received a deficiency letter from the Nasdaq notifying it that, based on its stockholders’
  evidence_url: https://www.sec.gov/Archives/edgar/data/811240/000119312524037654/0001193125-24-037654-index.htm
- Material Agreements
  BIOLASE, INC entered into Securities Purchase Agreement with certain institutional investors (effective 2024-02-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2024-02-13
  source text: the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) dated February 13, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the Securities sold in the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811240/000119312524037654/0001193125-24-037654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.